30 related articles for article (PubMed ID: 38640602)
1. A sensitive upconverting nanoprobe based on signal amplification technology for real-time in situ monitoring of drug-induced liver injury.
Meng L; Zheng X; Zheng Z; Zhao Z; Wang L; Zhou P; Xin GZ; Li P; Li HJ
Nanoscale; 2020 Jul; 12(28):15325-15335. PubMed ID: 32648877
[TBL] [Abstract][Full Text] [Related]
2. Dual-Acceptor-Based Upconversion Luminescence Nanosensor with Enhanced Quenching Efficiency for in Situ Imaging and Quantification of MicroRNA in Living Cells.
Yang L; Zhang K; Bi S; Zhu JJ
ACS Appl Mater Interfaces; 2019 Oct; 11(42):38459-38466. PubMed ID: 31593426
[TBL] [Abstract][Full Text] [Related]
3. Responsive Upconversion Nanoprobe for Background-Free Hypochlorous Acid Detection and Bioimaging.
Zhang R; Liang L; Meng Q; Zhao J; Ta HT; Li L; Zhang Z; Sultanbawa Y; Xu ZP
Small; 2019 Jan; 15(2):e1803712. PubMed ID: 30548763
[TBL] [Abstract][Full Text] [Related]
4. Upconversion luminescence-based aptasensor for the detection of thyroid-stimulating hormone in serum.
Liu J; Yu C; Han L; Shen Y; Fang Y; Xia Y; Yao X; Wu F; Li C; Chen J; Zhang X; Lan J
Mikrochim Acta; 2022 Apr; 189(5):179. PubMed ID: 35386003
[TBL] [Abstract][Full Text] [Related]
5. Single-step, homogeneous and sensitive detection for microRNAs with dual-recognition steps based on luminescence resonance energy transfer (LRET) using upconversion nanoparticles.
Zhu D; Miao ZY; Hu Y; Zhang XJ
Biosens Bioelectron; 2018 Feb; 100():475-481. PubMed ID: 28963965
[TBL] [Abstract][Full Text] [Related]
6. Ultrasensitive upconverting nanoprobes for in situ imaging of drug-induced liver injury using miR-122 as the biomarker.
Wang QL; Meng LC; Zhao Z; Du JF; Li P; Jiang Y; Li HJ
Talanta; 2024 Jul; 274():126108. PubMed ID: 38640602
[TBL] [Abstract][Full Text] [Related]
7. MiR-122 and other microRNAs as potential circulating biomarkers of drug-induced liver injury.
Howell LS; Ireland L; Park BK; Goldring CE
Expert Rev Mol Diagn; 2018 Jan; 18(1):47-54. PubMed ID: 29235390
[TBL] [Abstract][Full Text] [Related]
8. The diagnostic role of miR-122 in drug-induced liver injury: A systematic review and meta-analysis.
Liu Y; Li P; Liu L; Zhang Y
Medicine (Baltimore); 2018 Dec; 97(49):e13478. PubMed ID: 30544438
[TBL] [Abstract][Full Text] [Related]
9. Redox-Dependent HMGB1 Isoforms as Pivotal Co-Ordinators of Drug-Induced Liver Injury: Mechanistic Biomarkers and Therapeutic Targets.
Lea JD; Clarke JI; McGuire N; Antoine DJ
Antioxid Redox Signal; 2016 Apr; 24(12):652-65. PubMed ID: 26481429
[TBL] [Abstract][Full Text] [Related]
10. Novel biomarkers for potential risk stratification of drug induced liver injury (DILI): A narrative perspective on current trends.
Danjuma MI; Sajid J; Fatima H; Elzouki AN
Medicine (Baltimore); 2019 Dec; 98(50):e18322. PubMed ID: 31852121
[TBL] [Abstract][Full Text] [Related]
11. Drug Induced Liver Injury: Can Biomarkers Assist RUCAM in Causality Assessment?
Teschke R; Schulze J; Eickhoff A; Danan G
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28398242
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers of drug-induced liver injury: progress and utility in research, medicine, and regulation.
McGill MR; Jaeschke H
Expert Rev Mol Diagn; 2018 Sep; 18(9):797-807. PubMed ID: 30080986
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
